SOSTDC1

Summary

SOSTDC1 (sclerostin domain containing 1, HGNC:21748) is a protein-coding gene on chromosome 7p21.2, encoding Sclerostin domain-containing protein 1 (Q6X4U4). May be involved in the onset of endometrial receptivity for implantation/sensitization for the decidual cell reaction Enhances Wnt signaling and inhibits TGF-beta signaling.

This gene is a member of the sclerostin family and encodes an N-glycosylated, secreted protein with a C-terminal cystine knot-like domain. This protein functions as a bone morphogenetic protein (BMP) antagonist. Specifically, it directly associates with BMPs, prohibiting them from binding their receptors, thereby regulating BMP signaling during cellular proliferation, differentiation, and programmed cell death.

Source: NCBI Gene 25928 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 22 total
• MANE Select transcript: NM_015464

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21748
Approved symbol	SOSTDC1
Name	sclerostin domain containing 1
Location	7p21.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp564D206, USAG1, DAND7
Ensembl gene	ENSG00000171243
Ensembl biotype	protein_coding
OMIM	609675
Entrez	25928

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000307068, ENST00000396652

RefSeq mRNA: 1 — MANE Select: NM_015464 NM_015464

CCDS: CCDS5360

Canonical transcript exons

ENST00000307068 — 2 exons

Exon	Start	End
ENSE00001141528	16465464	16465738
ENSE00001896260	16461481	16462963

Expression profiles

Bgee: expression breadth ubiquitous, 227 present calls, max score 98.49.

FANTOM5 (CAGE): breadth broad, TPM avg 2.9833 / max 427.9260, expressed in 383 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
82890	1.7672	268
82891	0.5758	229
82892	0.5548	234
82888	0.0515	20
82889	0.0279	8
82893	0.0061	1

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	98.49	gold quality
retina	UBERON:0000966	98.46	gold quality
hair follicle	UBERON:0002073	98.21	gold quality
choroid plexus epithelium	UBERON:0003911	97.15	gold quality
parotid gland	UBERON:0001831	93.08	gold quality
upper leg skin	UBERON:0004262	90.68	gold quality
upper arm skin	UBERON:0004263	87.07	gold quality
lower lobe of lung	UBERON:0008949	85.96	silver quality
rectum	UBERON:0001052	85.87	gold quality
sperm	CL:0000019	85.70	silver quality
endothelial cell	CL:0000115	85.69	gold quality
mammalian vulva	UBERON:0000997	85.38	gold quality
right lung	UBERON:0002167	85.02	gold quality
epithelium of mammary gland	UBERON:0003244	84.26	gold quality
mucosa of sigmoid colon	UBERON:0004993	83.96	gold quality
mammary duct	UBERON:0001765	83.94	gold quality
renal medulla	UBERON:0000362	83.76	gold quality
jejunal mucosa	UBERON:0000399	83.67	gold quality
male germ cell	CL:0000015	82.68	silver quality
cervix squamous epithelium	UBERON:0006922	82.57	gold quality
lung	UBERON:0002048	82.35	gold quality
zone of skin	UBERON:0000014	82.00	gold quality
nephron tubule	UBERON:0001231	81.58	gold quality
mucosa of transverse colon	UBERON:0004991	81.58	gold quality
colonic mucosa	UBERON:0000317	81.43	gold quality
upper lobe of left lung	UBERON:0008952	81.35	gold quality
skin of abdomen	UBERON:0001416	81.22	gold quality
upper lobe of lung	UBERON:0008948	81.12	gold quality
duodenum	UBERON:0002114	81.01	gold quality
skin of hip	UBERON:0001554	80.73	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-11	yes	1768.00
E-ENAD-20	yes	718.01
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HOXA13, NFIL3, PAX3, SHH

miRNA regulators (miRDB)

83 targeting SOSTDC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-3121-3P	99.82	71.96	3630

Literature-anchored findings (GeneRIF, showing 23)

• Data suggest that ectodin is a novel bone morphogenetic protein (BMP) inhibitor which integrates BMP signaling with the SHH and FGF signal pathways (PMID:14623234)
• USAG1 is expressed in the kidney and functions as a bone morphogenetic protein antagonist. (PMID:15020244)
• This screen identified a bone morphogenetic protein (BMP) antagonist, SOSTDC1 (sclerostin domain-containing-1) as down-regulated in kidney tumors. (PMID:18032587)
• Loss of SOSTDC1 gene is associated with Wilms tumor. (PMID:19760604)
• genetic aberrations near SOSTDC1 are not uncommon in renal cancer, and occur in adult as well as pediatric renal tumors. (PMID:21080955)
• SOSTDC1 is expressed in normal breast tissue and this expression is reduced in breast cancer. (PMID:21113658)
• Results indicate for the first time that the genetic polymorphisms in SOSTDC1 have an effect on attainment and maintenance of peak bone mass in Chinese women. (PMID:21221677)
• DNA methylation is involved in the down-regulation of SOSTDC1 expression in gastric cancer. (PMID:23830730)
• Unliganded VDR upregulates the expression of hairless, the gene product of which acts as a downstream comodulator to feedback-repress DKKL1 and SOSTDC1. (PMID:24190897)
• Results conclude that the transcriptional repressor E4BP4 plays a role in repressing epigenetically regulated SOSTDC1 expression in breast cancer cells, which can be reverted by E4BP4 silencing. (PMID:25338303)
• Epigenetic silencing of SOSTDC1 through methylation is increased in prostate cancer and is associated with accelerated disease progression in patients with prostate cancer (PMID:25858146)
• Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2. (PMID:26378658)
• findings provide insight into the role of SOSTDC1 as a novel functional tumor suppressor in follicular thyroid cancer through modulating the activities of PI3K/Akt and MAPK/Erk signaling pathways. (PMID:28551845)
• The present study aimed to investigate SOSTDC1 coding regions in non-syndromic patients with one or more supernumerary teeth (PMID:30148467)
• SOSTDC1 may be a potential prognostic biomarker and therapeutic target for nonsmall cell lung cancer bone metastasis. (PMID:30320379)
• Study revealed upregulation of ADAMTS8 and downregulation of FRAS1 and SOSTDC1 in primary fibroblasts from linear morphoea (LM) lesions. SOSTDC1 knock-down recapitulated the reduced TGF -beta1 responsiveness and LM fibroblast migration, while overexpression of ADAMTS 8 induced myofibroblast markers. (PMID:30367460)
• Lack of association between SOSTDC1 gene polymorphisms and mesiodens (PMID:31133012)
• Downregulation of Sostdc1 in Testicular Sertoli Cells is Prerequisite for Onset of Robust Spermatogenesis at Puberty. (PMID:31391487)
• As rat Sostdc1 and human SOSTDC1 are dual antagonists of the Wnt/beta-catenin and BMP signaling pathways, these results underscore the potential crucial roles of these pathways and their antagonists, such as Sostdc1 and SOSTDC1, in developing and adult mammalian normal eyes as well as in syndromic and nonsyndromic congenital eye diseases. (PMID:31529323)
• Characterization of the different oligomeric states of the DAN family antagonists SOSTDC1 and SOST. (PMID:32779697)
• Impact of microRNA-21-5p on the growth of thyroid cancer cells via targeting the recombinant sclerostin domain containing protein 1.", trans “RNA-21-5p1. (PMID:34911834)
• Exosomal circ_0001190 Regulates the Progression of Gastric Cancer via miR-586/SOSTDC1 Axis. (PMID:35138469)
• SOSTDC1 acts as a tumor inhibitor in acute myeloid leukemia by downregulating the Wnt/beta-catenin pathway. (PMID:35442555)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	sostdc1b	ENSDARG00000056021
danio_rerio	sostdc1a	ENSDARG00000068892
mus_musculus	Sostdc1	ENSMUSG00000036169
rattus_norvegicus	Sostdc1	ENSRNOG00000005770

Paralogs (1): SOST (ENSG00000167941)

Protein

Protein identifiers

Sclerostin domain-containing protein 1 — Q6X4U4 (reviewed: Q6X4U4)

Alternative names: Ectodermal BMP inhibitor, Uterine sensitization-associated gene 1 protein

All UniProt accessions (2): A4D125, Q6X4U4

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the onset of endometrial receptivity for implantation/sensitization for the decidual cell reaction Enhances Wnt signaling and inhibits TGF-beta signaling. Directly antagonizes activity of BMP2, BMP4, BMP6 and BMP7 in a dose-dependent manner.

Subunit / interactions. Interacts with BMP2, BMP4, BMP6 and BMP7 with high affinity.

Subcellular location. Secreted.

Tissue specificity. Highly expressed in kidney and weakly in lung.

Similarity. Belongs to the sclerostin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6X4U4-1	1	yes
Q6X4U4-2	2

RefSeq proteins (1): NP_056279* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006207	Cys_knot_C	Domain
IPR008835	Sclerostin/SOSTDC1	Family
IPR029034	Cystine-knot_cytokine	Homologous_superfamily

Pfam: PF05463

UniProt features (23 total): sequence conflict 10, disulfide bond 4, glycosylation site 2, signal peptide 1, chain 1, splice variant 1, sequence variant 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6X4U4-F1	68.84	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 104–165, 75–133, 89–147, 100–163

Glycosylation sites (2): 47, 173

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 198 (showing top): GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, RRAGTTGT_UNKNOWN, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_MAMMARY_GLAND_MORPHOGENESIS, GOBP_EPIDERMIS_MORPHOGENESIS, GOBP_GLAND_MORPHOGENESIS, GOBP_MAMMARY_GLAND_EPITHELIUM_DEVELOPMENT, AREB6_01, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GGGTGGRR_PAX4_03, GOBP_DORSAL_VENTRAL_PATTERN_FORMATION, GOBP_SPECIFICATION_OF_SYMMETRY, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_REGULATION_OF_MYOBLAST_DIFFERENTIATION

GO Biological Process (16): pattern specification process (GO:0007389), negative regulation of cell fate commitment (GO:0010454), negative regulation of Wnt signaling pathway (GO:0030178), negative regulation of BMP signaling pathway (GO:0030514), hair follicle morphogenesis (GO:0031069), odontogenesis of dentin-containing tooth (GO:0042475), negative regulation of myoblast differentiation (GO:0045662), canonical Wnt signaling pathway (GO:0060070), mammary gland bud morphogenesis (GO:0060648), epithelial cell fate commitment (GO:0072148), negative regulation of canonical Wnt signaling pathway (GO:0090090), negative regulation of determination of dorsal identity (GO:2000016), Wnt signaling pathway (GO:0016055), BMP signaling pathway (GO:0030509), cell fate commitment (GO:0045165), negative regulation of cell differentiation (GO:0045596)

GO Molecular Function (2): BMP binding (GO:0036122), BMP receptor activity (GO:0098821)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell fate commitment	2
negative regulation of cell differentiation	2
Wnt signaling pathway	2
BMP signaling pathway	2
cell differentiation	2
multicellular organism development	1
multicellular organismal process	1
regulation of cell fate commitment	1
negative regulation of signal transduction	1
regulation of Wnt signaling pathway	1
regulation of BMP signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
negative regulation of cellular response to growth factor stimulus	1
hair follicle development	1
anatomical structure morphogenesis	1
hair cycle process	1
epidermis morphogenesis	1
odontogenesis	1
myoblast differentiation	1
regulation of myoblast differentiation	1
morphogenesis of an epithelial bud	1
mammary gland duct morphogenesis	1
epithelial cell differentiation	1
negative regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
determination of dorsal identity	1
negative regulation of multicellular organismal process	1
regulation of determination of dorsal identity	1
cell surface receptor signaling pathway	1
cellular response to BMP stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
cellular developmental process	1
regulation of cell differentiation	1
negative regulation of cellular process	1
negative regulation of developmental process	1
cytokine binding	1
transmembrane receptor protein serine/threonine kinase activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

406 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SOSTDC1	LRP5	O75197	880
SOSTDC1	DKK4	Q9UBT3	687
SOSTDC1	EDA	Q92838	591
SOSTDC1	BMP7	P18075	590
SOSTDC1	FOXI1	Q12951	584
SOSTDC1	LRP6	O75581	576
SOSTDC1	SHH	Q15465	560
SOSTDC1	WNT6	Q9Y6F9	554
SOSTDC1	BMP6	P22004	549
SOSTDC1	GREM2	Q9H772	543
SOSTDC1	BMP4	P12644	518
SOSTDC1	BMP2	P12643	507
SOSTDC1	EDAR	Q9UNE0	506
SOSTDC1	MSX2	P35548	481
SOSTDC1	CER1	O95813	480

IntAct

0 interactions, top by confidence:

BioGRID (32): BMP2 (Affinity Capture-Western), BMP4 (Affinity Capture-Western), BMP7 (Affinity Capture-Western), PLEC (Affinity Capture-MS), TACC1 (Affinity Capture-MS), SOSTDC1 (Affinity Capture-MS), TACC2 (Affinity Capture-MS), POF1B (Affinity Capture-MS), CEACAM5 (Affinity Capture-MS), SLC9A3R1 (Affinity Capture-MS), TLN2 (Affinity Capture-MS), SERPINB6 (Affinity Capture-MS), SERPINB12 (Affinity Capture-MS), DRG1 (Affinity Capture-MS), ATXN10 (Affinity Capture-MS)

ESM2 similar proteins: B5X1Q3, O54908, O93279, O94907, P12843, P13384, P18065, P24593, P24594, P24853, P47876, P47877, Q05717, Q07079, Q13145, Q1RMU1, Q28985, Q29400, Q2TJ95, Q3UTY6, Q5EGE1, Q5R328, Q5R3F8, Q5R5D2, Q5XHC5, Q642G2, Q68FM6, Q6UXI9, Q6VYA3, Q6X4U4, Q6ZMP0, Q76LD0, Q7TSK7, Q86TH1, Q8AVH7, Q8C8T7, Q8HYZ0, Q8IUX8, Q8VEJ3, Q91V88

Diamond homologs: Q5R5D2, Q642G2, Q6VYA3, Q6X4U4, Q99P67, Q99P68, Q9BG78, Q9BG79, Q9BQB4, Q9CQN4

SIGNOR signaling

20 interactions.

A	Effect	B	Mechanism
SOSTDC1	“down-regulates activity”	WNT3A
SOSTDC1	“down-regulates activity”	WNT8A
NFIL3	“down-regulates quantity by repression”	SOSTDC1	“transcriptional regulation”
SOSTDC1	“down-regulates activity”	WNT10A
SOSTDC1	“down-regulates activity”	WNT10B
SOSTDC1	“down-regulates activity”	WNT2B
SOSTDC1	“down-regulates activity”	WNT1
SOSTDC1	“down-regulates activity”	WNT4
SOSTDC1	“down-regulates activity”	WNT7A
SOSTDC1	“down-regulates activity”	WNT16
SOSTDC1	“down-regulates activity”	WNT11
SOSTDC1	“down-regulates activity”	WNT2
SOSTDC1	“down-regulates activity”	WNT5B
SOSTDC1	“down-regulates activity”	WNT3
SOSTDC1	“down-regulates activity”	WNT7B
SOSTDC1	“down-regulates activity”	WNT5A
SOSTDC1	“down-regulates activity”	WNT9B
SOSTDC1	“down-regulates activity”	BMP2
SOSTDC1	“down-regulates activity”	BMP4
SOSTDC1	“down-regulates activity”	BMP7

Disease & clinical

Clinical variants and AI predictions

ClinVar

22 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	15
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

289 predictions. Top by Δscore:

Variant	Effect	Δscore
7:16462959:CCGAG:C	acceptor_gain	1.0000
7:16462960:CGAG:C	acceptor_gain	1.0000
7:16462960:CGAGC:C	acceptor_gain	1.0000
7:16462961:GAG:G	acceptor_gain	1.0000
7:16462962:AG:A	acceptor_gain	1.0000
7:16462963:GC:G	acceptor_loss	1.0000
7:16462964:C:CC	acceptor_gain	1.0000
7:16462965:T:A	acceptor_loss	1.0000
7:16462974:C:CT	acceptor_gain	1.0000
7:16462975:A:T	acceptor_gain	1.0000
7:16465458:A:AC	donor_gain	1.0000
7:16465459:C:CC	donor_gain	1.0000
7:16465460:TTA:T	donor_loss	1.0000
7:16465461:TACTG:T	donor_loss	1.0000
7:16465462:A:AC	donor_gain	1.0000
7:16465462:ACTGT:A	donor_loss	1.0000
7:16465463:C:CG	donor_gain	1.0000
7:16465463:CT:C	donor_gain	1.0000
7:16465463:CTG:C	donor_gain	1.0000
7:16465463:CTGTT:C	donor_gain	1.0000
7:16527038:GCCGG:G	donor_gain	1.0000
7:16527039:CCGGG:C	donor_loss	1.0000
7:16527041:GG:G	donor_gain	1.0000
7:16527042:GG:G	donor_gain	1.0000
7:16527042:GGTA:G	donor_loss	1.0000
7:16527043:G:C	donor_loss	1.0000
7:16527043:G:GG	donor_gain	1.0000
7:16527044:T:TC	donor_loss	1.0000
7:16462967:C:CT	acceptor_gain	0.9900
7:16462968:A:T	acceptor_gain	0.9900

AlphaMissense

1362 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:16462671:C:A	K166N	1.000
7:16462671:C:G	K166N	1.000
7:16462674:G:C	C165W	1.000
7:16462675:C:G	C165S	1.000
7:16462675:C:T	C165Y	1.000
7:16462676:A:G	C165R	1.000
7:16462676:A:T	C165S	1.000
7:16462680:G:C	C163W	1.000
7:16462681:C:A	C163F	1.000
7:16462681:C:G	C163S	1.000
7:16462681:C:T	C163Y	1.000
7:16462682:A:G	C163R	1.000
7:16462682:A:T	C163S	1.000
7:16462711:C:G	R153P	1.000
7:16462728:G:C	C147W	1.000
7:16462729:C:G	C147S	1.000
7:16462729:C:T	C147Y	1.000
7:16462730:A:G	C147R	1.000
7:16462730:A:T	C147S	1.000
7:16462735:A:G	L145P	1.000
7:16462770:A:C	C133W	1.000
7:16462771:C:A	C133F	1.000
7:16462771:C:G	C133S	1.000
7:16462771:C:T	C133Y	1.000
7:16462772:A:G	C133R	1.000
7:16462772:A:T	C133S	1.000
7:16462776:C:A	W131C	1.000
7:16462776:C:G	W131C	1.000
7:16462778:A:G	W131R	1.000
7:16462778:A:T	W131R	1.000

dbSNP variants (sampled 300 via entrez): RS1000015750 (7:16463983 A>C), RS1000088697 (7:16464194 G>A), RS1000940345 (7:16466940 C>A), RS1001089128 (7:16462862 C>G,T), RS1001322708 (7:16462575 G>T), RS1001392708 (7:16467085 T>C,G), RS1002441945 (7:16467143 A>G), RS1002494210 (7:16467377 G>T), RS1002726313 (7:16461019 A>G), RS1002982157 (7:16466143 G>A), RS1003391143 (7:16466498 A>G), RS1004172519 (7:16466479 A>G,T), RS1004504535 (7:16466069 G>A,C), RS1005093905 (7:16464716 A>G), RS1005564704 (7:16461849 A>G)

Disease associations

OMIM: gene MIM:609675 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST000635_24	Response to statin therapy	9.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
entinostat	affects cotreatment, decreases expression	2
Estradiol	affects cotreatment, decreases expression, affects expression	2
Nickel	decreases expression	2
pirinixic acid	increases activity, affects binding, decreases expression	1
bisphenol A	decreases methylation, affects cotreatment	1
decabromobiphenyl ether	affects expression	1
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	decreases expression	1
dorsomorphin	increases expression, affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Vorinostat	increases expression	1
Benzo(a)pyrene	increases methylation	1
Copper	affects cotreatment, decreases expression	1
Ethinyl Estradiol	affects expression	1
Tamoxifen	affects expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
Aflatoxin B1	increases methylation	1
Genistein	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.